Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. develops clinical-stage antiviral therapeutics based on its nanoviricide technology and host-mimetic nanomedicine approach. Company news centers on NV-387, its lead broad-spectrum antiviral candidate, including clinical development for MPox, respiratory viral infections, measles and other viral diseases, as well as manufacturing updates for clinical product forms such as NV-387 Oral Gummies.
Recurring updates also cover FDA orphan-drug designation activity, rare-disease regulatory strategy, investor-conference participation and the company’s relationship with TheraCour Pharma for antiviral drug development technology. The news flow is focused on antiviral pipeline progress, regulatory designations and disease-area positioning rather than commercial product sales.
NanoViricides (NYSE American: NNVC) closed a registered direct offering to a single institutional investor, raising aggregate gross proceeds of approximately $2,000,001.
The securities were priced at-the-market at $1.50 per share with accompanying warrants exercisable at $1.75 per share after six months, expiring in three years.
NanoViricides (NYSE American: NNVC) highlights NV-387, a broad-spectrum antiviral, as a potential oral treatment for the Bundibugyo Ebola outbreak in eastern DRC and Uganda. NV-387 is designed to mimic sulfated proteoglycans used by filoviruses for cell attachment.
The drug is room‑temperature stable, formulated as oral gummies, and is being advanced toward Phase II clinical trials for respiratory and poxvirus infections. NanoViricides holds broad exclusive licenses for antiviral nanomedicine technology from TheraCour and is developing candidates against multiple serious viral diseases.
NanoViricides (NYSE American: NNVC) entered a securities purchase agreement with a single institutional investor for a registered direct offering expected to raise approximately $2 million in gross proceeds.
The deal includes common shares (or pre-funded warrants) plus warrants to purchase 1,333,334 shares at $1.75, expiring three years after issuance. Closing is expected around May 18, 2026.
NanoViricides (NYSE Amer: NNVC) filed its Q1 2026 Form 10-Q and reported progress on lead antiviral NV-387.
ACOREP approved a Phase II MPox trial in the DRC, and the FDA granted Orphan Drug Designation for NV-387 in Measles. The company reported $3.38M in cash, $10.20M in total assets, $1.07M in current liabilities, and $5.58M net cash used over nine months, with funding sufficient to complete the MPox Phase II trial but not all planned programs through May 14, 2027.
NanoViricides (NYSE American: NNVC) highlights global hantavirus risks and promotes its broad-spectrum antiviral candidate NV-387. The drug has completed a Phase I safety trial in healthy volunteers and is being advanced toward Phase II, targeting over 90% of pathogenic viral infections, according to NanoViricides.
NanoViricides (NYSE American: NNVC) will participate in the D. Boral Capital Global Conference on May 7, 2026 at The Plaza Hotel, New York City. Anil R. Diwan, PhD, President & Exec. Chairman, will host one-on-one meetings from 9:45 A.M. to 2:45 P.M. ET.
Interested parties should contact the DBC Conference Team to register for meetings.
NanoViricides (NYSE American: NNVC) announced that its clinical-stage antiviral NV-387 received Orphan Drug Designation from the US FDA OOPD for the treatment of measles on May 4, 2026. The designation confers tax credits, certain fee exemptions, and potential seven-year market exclusivity if approved.
The company also applied for Rare Pediatric Disease Drug designation and highlights in vivo efficacy in a humanized animal model; NV-387 is being advanced toward Phase II studies.
NanoViricides (NYSE:NNVC) highlighted rising measles outbreaks and presented NV-387 as a candidate treatment. Bangladesh reported 18,219 suspected cases (Mar 15–Apr 14, 2026) with 2,897 confirmed and 164 suspected deaths. The company cites NV-387 safety from a completed Phase I trial and efficacy in humanized lethal-measles animal models.
NanoViricides says it has applied for Orphan Drug and Rare Pediatric Disease designations for measles and notes a potential Priority Review Voucher value of $150–200M. The company plans to advance NV-387 toward Phase II but cannot yet set an IND filing date.
NanoViricides (NYSE:NNVC) filed a Rare Pediatric Disease Drug (RPDD) designation application for NV-387 as a treatment for measles on April 7, 2026, to be considered alongside an earlier Orphan Drug application.
The company noted potential eligibility for a tradable Priority Review Voucher (PRV) worth roughly $160M if approved, and cited rising U.S. measles cases and pediatric incidence supporting the RPDD case.
NanoViricides (NYSE American:NNVC) announced a Phase II clinical trial of NV-387 for MPox will begin soon in the Democratic Republic of Congo following ACOREP approval. CRO site prep and staff training are scheduled in early April 2026, with enrollment and dosing to commence after training. The company has applied for US FDA Orphan Drug Designation and cites potential economic benefits and Strategic National Stockpile opportunities.